|
Prostate Cancer
Series: Emerging Cancer Therapeutics V2 I3
James L. Gulley, MD, PhD, FACP, Jame Abraham, MD
Published 12/2011
200 pp Hardback
ISBN13 9781936287468
Price: $89.00
eISBN 9781935281917 |
Amazon Kindle | Google eBook
|
Description
A Doody's Core Title 2012
Emerging Cancer Therapeutics is a trinary, hard cover, periodical that is designed to provide an up-to-date evidence-based review of a dedicated emerging cancer therapy topic of interest to clinicians and scientists who are involved in the care of patients receiving cancer treatment. It will serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinical oncologists, radiation oncologists, surgical oncologists, cancer biologists, and interdisciplinary colleagues throughout the oncology spectrum. With contributions from experts across the United States and Canada, Prostate Cancer details the current management of prostate cancer and reviews new therapies in development for prostate cancer, with an emphasis on castration-resistant prostate cancer (CRPC). Coverage includes discussion of multiple new agents that have been shown to impact overall survival or improve skeletal-related events in metastatic CRPC as well as articles covering new data on screening and prevention, integration of surgery and radiation with newly emerging medical therapies, and coverage of the newest developments in immunotherapy. This book is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows. Included in Prostate Cancer: - Updates in Prostate Cancer Prevention
- Prostate Cancer Screening, 2011
- Current Surgical Approaches to Primary Prostate Cancer Treatment
- Updates in Radiation Therapy for Prostate Cancer: Dose Matters
- An Update on Androgen-Deprivation Therapy for Advanced Prostate Cancer
- Novel Androgen Receptor Therapeutic Targets for Advanced Prostate Cancer
- New Understanding of Metabolic Complications of Androgen-Deprivation Therapy
- Current State of Docetaxel-Based Therapy in Castration-Resistant Prostate Cancer
- Second-Line Chemotherapy for Castration-Resistant Prostate Cancer
- Emerging Role of Immunotherapy in the Treatment of Prostate Cancer
- Novel Bone-Targeted Therapy in Metastatic Prostate Cancer
- Emerging Treatment Strategies for Metastatic Prostate Cancer: The Next Step Forward
- return to top -
Contents Updates in Prostate Cancer Prevention, Howard L. Parnes, Margaret G. House, and Joseph A. Tangrea, Prostate Cancer Screening, 2011, Otis W. Brawley, Current Surgical Approaches to Primary Prostate Cancer Treatment, Mark R. Anderson, David I. Chu, Zarine R. Balsara, Michael N. Ferrandino, and Judd W. Moul, Updates in Radiation Therapy for Prostate Cancer: Dose Matters, Evan C. White, Mitchell Kamrava, Christopher R. King, Patrick Kupelian, D. Jeffrey Demanes, and Michael Steinberg, An Update on Androgen-Deprivation Therapy for Advanced Prostate Cancer, Xiao Su, Sanjaykumar Hapani, and Shenhong Wu, Novel Androgen Receptor Therapeutic Targets for Advanced Prostate Cancer, Cindy H. Chau and William D. Figg, New Understanding of Metabolic Complications of Androgen-Deprivation Therapy, Joelle El-Amm and Jeanny B. Aragon-Ching, Current State of Docetaxel-Based Therapy in Castration-Resistant Prostate Cancer, B. A. Adesunloye and W. L. Dahut, Second-Line Chemotherapy for Castration-Resistant Prostate Cancer, Sumanta Kumar Pal, Bassam M. Maalouf, and Oliver Sartor, Emerging Role of Immunotherapy in the Treatment of Prostate Cancer, Charles G. Drake, Novel Bone-Targeted Therapy in Metastatic Prostate Cancer, Jean-Baptiste Lattouf and Fred Saad, Emerging Treatment Strategies for Metastatic Prostate Cancer: The Next Step Forward, Christopher R. Heery, Marijo Bilusic, and Ravi A. Madan- return to top -
About the Guest Editors
James L. Gulley, MD, PhD, FACPDirector, Clinical Immunotherapy Group, Senior Investigator, National Cancer InstituteJame Abraham, MDBonnie Wells Wilson Distinguished Professor and Eminent Scholar, Chief, Section of Hematology-Oncology, Medical Director, Mary Babb Randolph Cancer Center
West Virginia University
|
|